The medical-aesthetics market, treatments aimed at improving patients’ cosmetic appearance, has a bright future. Senior partner Olivier Leclerc and colleagues find that CAGR for neuromodulators such as Botox is expected to reach 11.9 percent by 2025 in the United States and Canada. CAGR for dermal filler injectables such as hyaluronic acid fillers and biostimulators could reach 3.8 percent by 2025.
Image description:
A pair of stacked bar graphs shows the annual number and market size of neuromodulator and dermal-filler injectable procedures in Canada and the United States from 2019 to 2023, with estimates to 2025. The first graph shows the number of procedures being 11.7 million in 2019 and 19.9 million in 2023, with a projection of 23.0 million in 2025. The second graph shows the market size of procedures being $2.7 billion in 2019 and $4.4 billion in 2023, with a projection of $5.2 billion in 2025. Source: Aesthetic injectables—Market Insights—North America, Clarivate, October 2023.
End of image description.
To read the article, see “Here to stay: An attractive future for medical aesthetics,” February 1, 2024.